DOJ

U.S. Attorney for the District of Massachusetts, Carmen Ortiz, emphasized the importance of compliance programs early on during…

The U.S. Department of Justice (DOJ) recently announced a $40.1 million final settlement agreement with CareFusion Corp. to…

At the recent CBI Pharmaceutical Compliance Congress, U.S. Attorney for the District of New Jersey, Paul Fishman, discussed…

In his remarks at the CBI Pharmaceutical Compliance Congress, Assistant Attorney General, Civil Division, Stuart Delery emphasized…

Gigantic settlement figures, such as the $2.6 billion fine leveled on J.P. Morgan last week, may not be all they appear. Senators…

Novartis Pharmaceuticals has been accused by the U.S. government and 26 states of a kickback scheme related to its iron-reduction…

A recent slew of Federal Claims Act (FCA) complaints may be the norm as whistleblowers are bringing more and more cases against…

Compliance managers at pharmaceutical companies and medical device manufacturers can stay ahead of enforcement trends by…

On November 4, 2013, the Department of Justice (DOJ) announced that Johnson & Johnson (J&J) and its pharmaceutical…

The Food and Drug Law Institute (FDLI) recently held its annual Advertising & Promotion Conference, which included in-depth…